CJC-1295 (NO DAC) + Ipamorelin Blend Research Protocols & Administration Dosing in Published Research Research investigations have employed diverse dosing strategies for both peptides depending on species, research objectives, and desired pharmacodynamic effects: CJC-1295 (NO DAC) Research Doses: Human studies: 30-90 mcg/kg weekly doses in Phase I/II trials Rat models: 1 mcmol/kg subcutaneous administration for acute studies Cell culture: Picomolar to micromolar concentrations for in vitro growth hormone release assays Ipamorelin Research Doses: Human volunteers: 4.21-140.45 nmol/kg infused over 15 minutes in pharmacokinetic studies Rat models: 18-450 mcg/day divided into three daily doses in longitudinal studies Swine models: 2.3-3.9 nmol/kg effective doses for growth hormone release Combination Blend Research Protocols: Typical research ratios employ 1:1 to 2:1 (Ipamorelin:CJC-1295) by mass Daily to twice-daily administration protocols for sustained effects in animal models Weekly to twice-weekly dosing for CJC-1295 component in some research designs Important: These are experimental doses used in animal studies and early human research and cannot be extrapolated to other species or therapeutic applications due to significant differences in peptide metabolism, receptor density, pharmacokinetics, and species-specific growth hormone regulation
The Wolverine Stack The Wolverine Stack typically combines BPC-157 and TB-500, making it one of the most recognised peptide combinations within research communities
[DOI] [PMC free article] [PubMed] [Google Scholar] Traor D
Aliquot reconstituted peptides into single-use volumes to avoid repeated freeze-thaw cycles that can degrade peptides
Many foods are fortified with artificial vitamin B12, such as non-dairy milks and cereals, but these are not always optimally absorbed, so vegans must still be proactive about making sure they are not becoming deficient
However, if the research demands medical oversight for administration, injectables might be feasible
